CD4 and plasma cell myeloma: Our study strengthens the suggestion that myeloma growth disrupts both the qualitative and quantitative expression of immune checkpoints in the PB CD4+ T cell subsets, which may complicate the clinical response to therapeutic checkpoint inhibitors.